This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Bioxytran and Khoury Medical A-SUQAR...
Business Distribution agreement

Bioxytran and Khoury Medical A-SUQAR Distribution

Analysis based on 7 articles · First reported Feb 17, 2026 · Last updated Feb 18, 2026

Sentiment
40
Attention
2
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

This distribution agreement is expected to positively impact Bioxytran by providing recurring commercial revenue and validating its technology platform. It also opens up new market opportunities for Khoury Medical in the dietary supplement sector.

Biotechnology Pharmaceuticals Nutraceuticals
Event Summary

Bioxytran, Inc., a biotechnology company, has announced a commercial Distribution Agreement with Khoury Medical LTD. Under this agreement, Khoury Medical will commercialize A-SUQAR, a chewable dietary supplement developed by Bioxytran, in permitted markets. This move signifies Bioxytran's transition from a development-stage organization to one with commercial revenue, validating its proprietary carbohydrate-based galectin platform. The agreement focuses solely on non-pharmaceutical dietary products, allowing Bioxytran to continue advancing its pharmaceutical and antiviral programs independently. Both companies anticipate initial commercial shipments to commence soon, addressing a global market demand for the A-SUQAR line.

Key Actions
100 Bioxytran entered into a commercial Distribution Agreement Khoury Medical
95 Khoury Medical will commercialize A-SUQAR Bioxytran
Entities Involved
stock
Bioxytran
Bioxytran has entered into a commercial Distribution Agreement with Khoury Medical LTD for its A-SUQAR dietary supplement. This agreement marks a significant milestone for Bioxytran, transitioning it from a development-stage organization to one with recurring commercial revenue. It also validates their proprietary carbohydrate-based galectin platform.
Importance 100 Sentiment 50
priv
Khoury Medical
Khoury Medical will commercialize Bioxytran's A-SUQAR dietary supplement in permitted markets. This collaboration allows Khoury Medical to bring a differentiated, science-informed product to market, addressing a meaningful consumer need.
Importance 90 Sentiment 40
per
David Platt
As CEO of Bioxytran, David Platt views this agreement as an important milestone for the company, signifying a transition to recurring commercial revenue and validating their galectin platform.
Importance 60 Sentiment 30
per
Nassar Khoury
As CEO of Khoury Medical LTD, Nassar Khoury believes this collaboration will bring a differentiated product to market and addresses a meaningful consumer need.
Importance 60 Sentiment 30
Relationships
Bioxytran related ↔ Khoury Medical
David Platt related ↔ Bioxytran
Nassar Khoury related ↔ Khoury Medical
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.